Aegis Capital Initiates Coverage On ATAI Life Sciences with Buy Rating, Announces Price Target of $26
Aegis Capital analyst Nathan Weinstein initiates coverage on ATAI Life Sciences (NASDAQ:ATAI) with a Buy rating and announces Price Target of $26.
58 Biggest Movers From Friday
Gainers
CAI International, Inc. (NYSE: CAI) shares surged 46.9% to close at $56.05 on Friday after the company agreed to a $1.1 billion takeover by Mitsubishi HC Capital Inc.
Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public
Atai Life Sciences (NASDAQ: ATAI), a biotech company in the psychedelic space, had its Nasdaq debut on Friday.
List Of Initial Public Offerings For Friday, Jun. 18, 2021
AiHuiShou International (RERE)
Century Therapeutics (IPSC)
ATAI Life Sciences (ATAI)
Jaws Juggernaut Acquisition (JUGGU)
Tremor International (TRMR)
Ambrx Biopharma (AMAM)
Cyteir Therapeutics (CYT)
Codex DNA
IPO Preview: WalkMe, Atai Life Sciences Highlight Week Of Many Offerings
This week’s IPO lineup could feature a double digit number of companies hitting the public. Here is a look at some of the largest and most high profile companies going public this week.
Peter Thiel-Backed Psychedelic Firm Atai Sets Terms For US IPO, Sees $2.3B Valuation
Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, has announced terms for its initial public offering.